Efficacy of hydroxypropyl cellulose ophthalmic inserts (LACRISERT) in subsets of patients with dry eye syndrome: Findings from a patient registry

Cornea

Volumn 29, Issue 12, 2010, Pages 1417-1427

  Luchs, Jodi I ^a   Nelinson, Donald S ^b   Macy, Jonathan I ^c  

^a South Shore Eye Care   (United States)

^b InterQuest Medical   (United States)

^c Macy Eye Center   (United States)

Author keywords

dry eye syndrome; LACRISERT; OSDI; patient registry; quality of life

Indexed keywords

HYDROXYPROPYLCELLULOSE; LACSISERT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLURRED VISION; CATARACT; CATARACT EXTRACTION; CONTACT LENS; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY EYE; EPIPHORA; EYE DISCOMFORT; EYE IRRITATION; EYE SWELLING; EYELASH CRUSTING; EYELASH STICKINESS; EYELID SWELLING; FEMALE; FOREIGN BODY SENSATION; GLAUCOMA; HUMAN; KERATOMILEUSIS; LASER EPITHELIAL KERATOMILEUSIS; LASER SURGERY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OCULAR ACHE; OCULAR GRITTINESS; OCULAR STINGING; OCULAR SURFACE DISEASE INDEX; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; REFRACTIVE SURGERY; SCORING SYSTEM; UNSPECIFIED SIDE EFFECT;

ACTIVITIES OF DAILY LIVING; CATARACT; CELLULOSE; CONTACT LENSES; DRUG IMPLANTS; DRY EYE SYNDROMES; FEMALE; GLAUCOMA; HUMANS; KERATOMILEUSIS, LASER IN SITU; MALE; MIDDLE AGED; PATIENT COMPLIANCE; QUALITY OF LIFE; QUESTIONNAIRES; REGISTRIES; TEARS; TREATMENT OUTCOME;

EID: 78650512958     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e3181e3f05b     Document Type: Article

References (13)

1. The definition and classification of dry eye disease: Report of the definition and classification subcommittee of the international dry eye workshop (2007). Ocul Surf. 2007;5:75-92.
2. Lemp MA. Advances in understanding and managing dry eye disease. Am J Ophthalmol. 2008;146:350-356.
3. The epidemiology of dry eye disease: Report of the epidemiology subcommittee of the international dry eye workshop (2007). Ocul Surf. 2007;5:93-107.
4. Leung EW, Medieros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17:350-355.
5. Ram J, Gupta A, Brar GS, et al. Outcomes of phacoemulsification in patients with dry eye. J Cataract Refract Surg. 2002;28:1386-1389.
6. Ram J, Sharma A, Pandav SS, et al. Cataract surgery in patients with dry eyes. J Cataract Refract Surg. 1998;24:1119-1124.
7. Donnenfeld E, Pflugflelder SC. Topical ophthalmic cyclosporine: Pharmacology and clinical uses. Surv Ophthalmol. 2009;54:321-338.
8. Toda I. LASIK and the ocular surface. Cornea. 2008;27(Suppl 1):S70-S76.
9. Sindt CW, Longmuir RA. Contact lens strategies for the patient with dry eye. Ocul Surf. 2007;5:294-307.
10. LACRISERT [package insert]. Lawrenceville, NJ: Aton Pharmaceuticals Inc; 2007.
11. Schiffman RM, Christianson MD, Jacobsen G, et al. Reliability and validity of the ocular surface disease index. Arch Ophthalmol. 2000;118:615-621.
12. Henry JC, Peace JH, Stewart JA, et al. Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy. Clin Ophthalmol. 2008;2:613-621.
13. Stonecipher K, Ignacia TS, Stonecipher M. Advances in refractive surgery: Microkeratome and femtosecond laser flap creation in relation to safety, efficacy, predictability, and biomechanical stability. Curr Opin Ophthalmol. 2006;17:368-372.